Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
135 Results for "
PDMS interfaces
" in MedChemExpress (MCE) Product Catalog:
Products (135)
135 Results for "PDMS interfaces" in MCE Product Catalog:
Cat. No.: HY-181157
Target:
Research Areas:
T/E PPI-IN-1 (Compound C87) is a TRIM28-EZH2 interaction inhibitor targeting reactive cysteines at the interface. T/E PPI-IN-1 can be used for the research of cancer .
Cat. No.: HY-183371
CAS No.: 864868-22-4
Target:
Research Areas:
ZINC13407541 is a fibroblast growth factor 23 (FGF23) antagonist with an IC50 of 0.45 μM. ZINC13407541 preferentially binds to the FGF23:FGFR interface to disrupt their protein-protein interactions. ZINC13407541 can be used for the research of hypophosphatemia .
Cat. No.: HY-173121
KR019 is a potent HBV capsid assembly modulator, exhibits potent antiviral activity in HBV-replicating cells. KR019 binds to the hydrophobic pocket at the core protein dimer-dimer interface, misdirecting capsid assembly into genome-free capsids and thereby inhibiting viral replication .
Cat. No.: HY-183293
Target:
Research Areas:
Cbl-b-IN-32 is a Cbl-b inhibitor with an IC50 of 6.83 μM. Cbl-b-IN-32 binds to the TKB-LH interface, stabilizes the inactive conformation of Cbl-b, engages Tyr363 via hydrogen bonds and water bridges, and forms hydrogen bonds with Phe261 and Phe263 .
Cat. No.: HY-129165
CAS No.: 618361-63-0
Target:
Research Areas:
ZINC08383544 is a PKM2 activator with anti-tumor activity. ZINC08383544 binds to the dimer-dimer interface of PKM2, promotes tetramer formation, blocks nuclear translocation, inhibits the expression of glycolysis-related genes such as GLUT1, and reduces T cell-mediated inflammatory responses. ZINC08383544 can be used in cancer-related research such as cervical cancer .
Cat. No.: HY-179706
CAS No.: 2576427-49-9
VS3 is a YAP-TEAD interaction inhibitor. VS3 directly disrupts the interaction between YAP-TEAD by binding to TEAD4 Interface 3 (Kd = 6 μM) on the surface. VS3 exhibits anti-proliferative activity against HT29, HCT116, and A2780. VS3 can be used for research on colorectal adenocarcinoma and ovarian cancer .
Cat. No.: HY-W663542
CAS No.: 89366-02-9
Cat. No.: HY-181657
CAS No.: 3102899-89-5
Target:
Research Areas:
EGFR-IN-200 is an inhibitor targeting EGFR, TNF-α, and the IL-6/GP130 complex, which potently targets human EGFR (IC50=0.03 μM), TNF-α (IC50=3.1 μM), and the IL-6/GP130 complex (IC50=1.6 μM). EGFR-IN-200 binds to the ATP pocket of EGFR, the trimer interface of TNF-α, and the cytokine-receptor interface of IL-6/GP130, induces G2/M cell cycle arrest, apoptosis, and antiproliferative activity. EGFR-IN-200 exhibits high gastrointestinal absorbability, low BBB permeability, and complies with the Lipinski's rule. EGFR-IN-200 can be used for the research of lung cancer and breast adenocarcinoma .
Cat. No.: HY-L0119V
3,253 compounds
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.
The PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics. The designs cover β-turn / loop mimetics and α-helix mimetics. Since helices present at the interface in 62% of all protein-protein interactions. This library focused on designs including mimics with the substitution geometry of an a-helices, as well as designs that mimic the location of “hot-spot” side chains in helix-mediated PPIs.
Cat. No.: HY-P11770
CAS No.: 1352117-55-5
Target:
Research Areas:
α-Tubulin (residues 440-451) (α-Tubulin Tail) is a Microtubule growth inhibitor. α-Tubulin (residues 440-451) transiently interacts with the longitudinal polymerization interface of α-tubulin, regulating the apparent association and dissociation rates of tubulin at the microtubule growing end. α-Tubulin (residues 440-451) inhibits microtubule growth .
Cat. No.: HY-131570
CAS No.: 1997359-63-3
Target:
Research Areas:
JZ-4109 is a β-Glucocerebrosidase (GCase) modulator with an IC50 of 8 nM for wild-type recombinant GCase. JZ-4109 binds to an allosteric site at the GCase dimer interface, stabilizes wild-type and GCase N370S mutant GCase, induces GCase dimerization. JZ-4109 increases GCase protein abundance. JZ-4109 can be used for the research of Parkinson's diseas .
Cat. No.: HY-102072
CAS No.: 1445801-61-5
Target:
Research Areas:
GKL003 is a bacterial transcription inhibitor that targets the RNAP-σ interaction interface, with a Ki of 5.79 nM. GKL003 specifically binds to the RNAP β' clamp helix region at the σ A factor binding site, blocks the formation of RNAP holoenzyme, and inhibits the formation of bacterial transcription initiation complexes. GKL003 inhibits the growth of both Gram-positive and Gram-negative bacterial cells, and also exhibits activity against drug-resistant strains .
Cat. No.: HY-118692
CAS No.: 299165-92-7
DCAI is a KRas inhibitor with a Kd value of 1.1 mM. DCAI directly binds to the Ras protein and competitively inhibits SOS-mediated nucleotide release (IC50 = 155 μM) and exchange reaction (IC50 = 342 μM). DCAI binds to the pocket at the Ras-SOS interface and blocks the formation of the Ras-SOS complex intermediate by impeding salt bridge formation through steric hindrance and the induction of Ras conformational changes. DCAI is used in the study of wild-type and mutant Ras tumors .
Cat. No.: HY-111550R
CAS No.: 342795-08-8
Target:
Research Areas:
Bragsin2 (Standard) is the analytical standard of Bragsin2 (HY-111550). This product is intended for research and analytical applications. Bragsin2 is a potent, selective and noncompetitive nucleotide exchange factor BRAG2 inhibitor, with an IC50 of 3 μM. Bragsin2 binds at the interface between the PH domain of BRAG2 and the lipid bilayer, leads BRAG2 unable to activate lipidated Arf GTPase. Bragsin2 affects breast cancer stem cells .
Cat. No.: HY-118692A
CAS No.: 1049742-84-8
DCAI hydrochloride is a KRas inhibitor with a Kd value of 1.1 mM. DCAI hydrochloride directly binds to the Ras protein and competitively inhibits SOS-mediated nucleotide release (IC50 = 155 μM) and exchange reaction (IC50 = 342 μM). DCAI hydrochloride binds to the pocket at the Ras-SOS interface and blocks the formation of the Ras-SOS complex intermediate by impeding salt bridge formation through steric hindrance and the induction of Ras conformational changes. DCAI hydrochloride is used in the study of wild-type and mutant Ras tumors .
Cat. No.: HY-182280
Target:
Research Areas:
BDM71230 is an orally active inducer of insulin-degrading enzyme (IDE), with an EC50 of 1.9 μM against human IDE. BDM71230 binds to the interface of IDE dimers and enhances the catalytic activity of IDE via steric effects. BDM71230 can potentiate the hydrolytic effect of IDE on insulin and slightly attenuate the hypoglycemic effect of insulin. BDM71230 serves as a pharmacological tool for investigating IDE function and is applicable to studies related to glucose intolerance .
Cat. No.: HY-181997
CAS No.: 3093624-24-6
LDLRAP1-IN-1 (Compound B19) is a LDLRAP1 inhibitor and antiviral agent, with an IC50 of 4.98 μM for disrupting the interaction between LDLRAP1 and LDLR. LDLRAP1-IN-1 covalently modifies the C119 residue of LDLRAP1 at the LDLRAP1-LDLR binding interface, thereby disrupting the interaction between LDLRAP1 and LDLR. LDLRAP1-IN-1 exhibits antiviral activity against HCoV-OC43 .
Cat. No.: HY-183988
Target:
Research Areas:
OICR409946 is a self-dimerization-induced proximity-targeting chimera (SDIPTAC) targeting DCAF1, with a Kd value of 6200 nM. OICR409946 binds to DCAF1, induces head-to-tail homodimerization, sterically blocks the Vpr binding interface, prevents the recruitment of Vpr to the CRL4DCAF1 complex, and inhibits Vpr-dependent HIV replication. OICR409946 can be used in studies related to HIV infection (DCAF1 ligand: (HY-169390); Linker: (HY-130659)) .
Cat. No.: HY-187584
CAS No.: 1044664-73-4
Target:
Research Areas:
LQZ-7 is a survivin inhibitor and molecular glue degrader (Kd=0.24 μM). LQZ-7 binds to the dimerization interface of survivin, disrupting homodimerization and dissociating dimeric survivin into monomers, thereby accelerating its proteasome-dependent degradation. LQZ-7 does not affect the structurally similar dimeric proteins 14-3-3σ and 14-3-3δ, and can induce apoptosis, exhibiting cytotoxicity against cancer cells .
Cat. No.: HY-120031
CAS No.: 299421-08-2
NSC-368262 is a STAT3 inhibitor. NSC-368262 selectively alkylates and covalently modifies STAT3 Cys468 at the DNA-binding interface of STAT3, blocks the DNA-binding activity of STAT3, and inhibits the phosphorylation of STAT3. NSC-368262 blocks the accumulation of activated STAT3 in the nucleus of cancer cells, induces PARP cleavage and apoptosis in cells, and inhibits tumor growth in mouse models. NSC-368262 can be used in research related to breast cancer and cervical cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
